future results, VRS-317 may not have favorable results in later clinical trials or receive regulatory approval.•Long-acting rhGH products and product candidates no longer in development or marketed have failed to generate commercial success or obtain regulatory
purchase additional shares in full, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.We intend to use approximately $50 million of the net proceeds from this offering, along with our other capital resources, to fund our ongoing and planned clinical development ofVRS-317,and the balance to fund working capital, capital expenditures and other general corporate purposes, which may include the acquisition or licensing of other products, businesses or technologies.
anticipated demand and reduce our cost of manufacturing, and that are compliant with current Good Manufacturing Practices, or cGMP, regulations;•our success in educating physicians and patients about the benefits, administration and use of VRS-317;•the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing treatments;•the effectiveness of our own or our potential strategic collaborators’ marketing, sales and distribution strategy and operations;•acceptance of VRS-317 as safe and effective by patients, caregivers and the medical community;•a continued acceptable safety profile of VRS-317 following approval; and•continued compliance with our obligations in our intellectual property licenses with third parties upon favorable terms.Many of these factors are beyond our control.
satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain regulatory approval for the marketing of their products.In addition, we have not yet confirmed that the selected Phase 3 dose of VRS-317 administered for 12 months will provide adequate efficacy to support registration.
experience delays in enrollment, our ability to complete our planned Phase 3 clinical trial could be impaired and the costs of conducting the study could increase, either of which could have a material adverse effect on our business.16Table of ContentsIndex to Financial StatementsIf clinical studies of VRS-317 and any future product candidates fail to demonstrate safety and
receive regulatory approval or commercialize VRS-317 or any future product candidates, including the following:•clinical studies may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical studies
side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following any marketing approval.Our product candidate, VRS-317, has not completed clinical development.
or any of our future product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result, including:•we may be forced to suspend the marketing of such product;•regulatory authorities may withdraw their approvals of such product;18Table of ContentsIndex to Financial Statements•regulatory authorities may require additional warnings on the label that could diminish the usage or otherwise limit the commercial success of such
may require the establishment or modification of a similar strategy that may, for instance, restrict distribution of our products and impose burdensome implementation requirements on us;•we may be required to change the way the product is administered or conduct additional clinical trials;•we could be sued and held liable for harm caused to subjects or patients;•we may be subject to litigation or product liability claims; and•our reputation may suffer.Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved.Even if our clinical trials demonstrate acceptable safety and efficacy of VRS-317 for growth in pediatric GHD patients based on a semi-monthly dosing regimen, the FDA or similar regulatory
fail to obtain FDA or other regulatory approval of VRS-317 or if the approval is narrower than what we seek, it could have a material adverse effect on our business, financial condition, results of operations and growth prospects.19Table of ContentsIndex to Financial StatementsEven if VRS-317 or any future product candidates receive regulatory approval, they may fail to achieve
The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including the following:•the prevalence and severity of any side effects;•their efficacy and potential advantages compared to alternative treatments;•the price we charge for our product candidates;•the willingness of physicians to change their current treatment practices;•convenience and ease of administration compared to alternative treatments;•the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;•the strength of marketing and distribution support; and•the availability of third-party coverage or reimbursement.For example, a number of companies offer therapies for treatment of pediatric GHD patients based on a daily regimen, and physicians, patients or their families may not be willing to change their current
candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities.
distribution;•the degree and rate of market acceptance of any products launched by us or future partners;•the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;•our ability to enter into additional collaboration, licensing, commercialization or other arrangements and the terms and timing of such arrangements;29Table of ContentsIndex to Financial Statements•the emergence of competing technologies or other adverse market developments; and•the costs of attracting, hiring and retaining qualified personnel.We do not have any material committed external source of funds or other support for our development efforts.
commercialize any products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business, including:•different regulatory requirements for drug approvals in foreign countries;•reduced protection for intellectual property rights;•unexpected changes in tariffs, trade barriers and regulatory requirements;•economic weakness, including inflation or political instability in particular foreign economies and markets;•compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;•foreign taxes, including withholding of payroll taxes;•foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business
manufacture VRS-317 at a competitive cost;•our ability to successfully build a specialty sales force and commercial infrastructure;•our ability to compete with companies currently producing rhGH therapies;•our reliance on third parties to conduct our clinical studies;•our reliance on third-party contract manufacturers to manufacture and supply our product candidates for us;•our reliance on our collaboration partners’ performance over which we do not have control;55Table of ContentsIndex to Financial Statements•our ability to retain and recruit key personnel, including development of a sales and marketing function;•our ability to obtain and maintain intellectual property protection for VRS-317 or any future product candidates;•the actual receipt and timing of any milestone payments or royalties from our collaborators;•our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing;•our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act;•our ability to identify, develop, acquire and in-license new products and product candidates;•our ability to successfully establish and successfully maintain appropriate collaborations and derive significant revenue from those collaborations;•our financial performance; and•developments and projections relating to our competitors or our industry.These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in “Risk